Biotech: Page 52

  • Lariner Square, Denver, Colorado
    Image attribution tooltip
    Permission granted by Regis University
    Image attribution tooltip
    Sponsored by Regis University

    Driving buses helped one biomedical science professional discover his passion — and Regis University

    Hunter Allen realized he loved the responsibility of caring for others. At Regis, he learned how to hone his passion and create healthy communities.

    Nov. 14, 2022
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    FDA declines to review Brainstorm’s ALS therapy

    It’s the latest setback for Brainstorm’s NurOwn, an engineered cell therapy that has been on a winding journey since failing a key study in ALS patients two years ago.

    By • Nov. 11, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

    By BioPharma Dive staff
  • A man in a suit and tie speaks during a press conference.
    Image attribution tooltip

    Kyodo/Newscom

    Image attribution tooltip

    Seagen picks Novartis, Flagship veteran Epstein as new CEO

    The hiring of David Epstein, who spent the last five years building startups at Flagship, suggested to some investors that a long-rumored acquisition by Merck may not be forthcoming.

    By • Nov. 10, 2022
  • Image attribution tooltip
    Brian Tucker/BioPharma Dive
    Image attribution tooltip

    Clovis warns of bankruptcy, lays off staff after up-and-down journey

    The warning, unusual for a company with a marketed drug, comes as the biotech is negotiating with creditors after skipping an interest payment.

    By Kristin Jensen • Updated Dec. 12, 2022
  • A man in a laboratory holds research equipment.
    Image attribution tooltip
    Permission granted by Faze Medicines / Marissa Fiorucci
    Image attribution tooltip

    Third Rock-backed Faze Medicines shutters two years after launch

    The biomolecular condensates-focused company is calling it quits after “the science did not progress sufficiently to meet our bar for further investment,” a spokesperson said.

    By • Nov. 10, 2022
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen names former Sanofi head Viehbacher to replace Vounatsos as CEO

    Viehbacher’s appointment ends a monthslong search by Biogen for new leadership and puts the embattled biotech on a new course after the disastrous launch of Aduhelm.

    By , • Updated Nov. 10, 2022
  • Image attribution tooltip
    "Numbers And Finance" by Ken Teegardin is licensed under CC BY-SA 2.0
    Image attribution tooltip

    Arrowhead capitalizes on Amgen drug progress with royalty rights deal

    The biotech will sell its royalty interest in a heart disease drug Amgen is developing for $250 million, extending its operating runway by several quarters.

    By • Nov. 9, 2022
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    BioMarin signals lengthier FDA review for hemophilia gene therapy

    The agency wants to see forthcoming study results for the biotech's treatment, which could potentially push out an approval decision by three months.

    By • Nov. 8, 2022
  • A photo of a sign inside an Apellis Pharmaceuticals building
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis defends change in regulatory plans for closely watched eye drug

    Shares have fallen more than 20% since Apellis chose to add new data to its U.S. submission, delaying the drug’s review in geographic atrophy. But on a conference call, executives argued the benefits are worth the cost.

    By • Nov. 8, 2022
  • Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Amgen to test new way to lower heart risk with large drug trial

    Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).

    By • Nov. 7, 2022
  • Woman in white coat looking at data ang line charts on monitors
    Image attribution tooltip
    Permission granted by QIAGEN
    Image attribution tooltip
    Sponsored by QIAGEN

    Cell line characterization and selection made easy

    Build confidence and efficiency into your research with traceable and reliable cell line 'omics data.

    Nov. 7, 2022
  • The entrance to Galapagos' corporate offices are lit up at dusk.
    Image attribution tooltip
    Courtesy of Galapagos
    Image attribution tooltip

    Galapagos to cut 200 jobs amid research revamp

    The workforce reduction is part of a “new strategic direction” for Galapagos, which intends to stop developing drugs for fibrosis and kidney disease.

    By • Nov. 4, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor.
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip

    Artiva cancels IPO plans and cuts a deal with Affimed

    With public offerings difficult to pull off, Artiva is focusing its energy on developing a cancer drug with the German biotech.

    By • Nov. 3, 2022
  • A still from a video of three women and two men talking.
    Image attribution tooltip
    Colin Babej / BioPharma Dive/BioPharma Dive
    Image attribution tooltip

    Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

    In a panel discussion hosted by BioPharma Dive, venture capitalists and CEOs discuss how startups can navigate a challenging market as well as possible ripple effects from the new U.S. drug pricing law.

    By , • Nov. 3, 2022
  • A science lab with no workers
    Image attribution tooltip
    alvarez via Getty Images
    Image attribution tooltip

    Rubius replaces CEO as it cuts more jobs and considers a sale

    The struggling biotech’s CFO and top lawyer are also departing amid a new round of layoffs for a company formed by Flagship Pioneering and once worth nearly $2 billion.

    By Kristin Jensen • Nov. 3, 2022
  • A financial graph on an abstract background
    Image attribution tooltip
    monsitj via Getty Images
    Image attribution tooltip

    Surface Oncology to lay off 20% of staff in restructuring

    In cutting jobs, the biotech joins a lengthening list of drug companies forced to trim their workforce this year. It plans to stop work on an antibody cancer drug to focus resources on two other candidates.

    By • Nov. 2, 2022
  • A grey exterior sign with Alkermes' written on it sits in a bed of flowers outside a glass office building.
    Image attribution tooltip
    Permission granted by Karissa Waddick
    Image attribution tooltip

    Alkermes, continuing transformation, plans to split in two

    The biotech’s transition from drug delivery specialist to maker of novel medicines led to competing neuroscience and oncology divisions. The latter will soon become a separate company.

    By • Nov. 2, 2022
  • A toad hides under a rock
    Image attribution tooltip
    makasana via Getty Images
    Image attribution tooltip

    RA Capital backs another startup hunting for a better antidepressant

    Lusaris Therapeutics is launching with $60 million to develop an under-the-tongue form of 5-MeO-DMT, a psychoactive compound found in the glands of the Sonoran Desert toad.

    By • Nov. 2, 2022
  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    CSL bets on mRNA vaccines in deal with Arcturus

    The drugmaker agreed to pay $200 million upfront and potentially billions more to license the technology and knowhow from Arcturus to make preventive shots for COVID-19, influenza and other respiratory infections.  

    By Kristin Jensen • Nov. 2, 2022
  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by HI-Bio
    Image attribution tooltip

    Armed with $120M, HI-Bio joins race to develop better autoimmune disease drugs

    HI-Bio, incubated by Arch and holding rights to two drugs from MorphoSys, is one of several recently launched startups to tout a precision medicine approach to treating inflammatory disease.

    By • Nov. 1, 2022
  • An illustration of a herpes simplex virus
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Replay launches gene therapy spinout Eudora, putting ‘hub-and-spoke’ plans to work

    The public debut of Eudora comes three months after Replay emerged with $55 million and gene delivery technology it claims can outperform AAV viral vectors.

    By • Oct. 31, 2022
  • Colleagues collaborating in an office
    Image attribution tooltip
    Permission granted by QIAGEN
    Image attribution tooltip
    Sponsored by QIAGEN

    Boost agility and speed in your drug development research

    How flexible API access to integrated 'omics data helps boost agility and speed in drug research.

    Oct. 31, 2022
  • Image attribution tooltip
    Gilead Sciences Inc. / Kite Pharma
    Image attribution tooltip

    Gilead, fueled by latest approval, sees CAR-T sales take off

    After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and J&J.

    By • Oct. 28, 2022
  • Two lab scientists work inside a research facility. A man turns to talk to his colleague, who is seated.
    Image attribution tooltip
    Permission granted by Landmark Bio
    Image attribution tooltip

    An unusual alliance opens a gene and cell therapy hub outside Boston

    Landmark Bio, armed with $75 million and a wide range of backers, is the latest company to emerge with plans to open a “bottleneck” to development of the complex medicines.

    By • Oct. 27, 2022
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    For Biogen investors, company’s outlook rests on next Alzheimer’s drug

    Analysts pressed the company during its latest earnings presentation for more details about the Alzheimer’s drug it’s developing with Eisai — and how the partners plan to avoid some of the pitfalls experienced with Aduhelm. 

    By • Oct. 25, 2022